ArticleEClinicalMedicine2024

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Zhi-Cheng Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.